Skip to main content

Table 3 Administered treatment

From: Treatment outcome of intravenous artesunate in patients with severe malaria in the Netherlands and Belgium

Variable Number of patients (ntotal = 68)
Initial treatment, n (%)  
Artesunate 43 (63)
   monotherapy 39 (57)
   + clindamycin 2 (3)
   + doxycycline 2 (3)
Quinine 19 (28)
AP 2 (3)
AL 2 (3)
SP + doxycycline 1 (2)
Unknown oral anti-malarial 1 (2)
Artesunate  
Median number of doses (range) 3 (1-7)
Median cumulative dose (range), mg 600 (120-1320)
Median cumulative dose/bodyweight (range), mg/kg 7.5 (2.3-18.1)
Oral anti-malarial drug after artesunate, n (%)  
AP 41 (60)
AL 20 (29)
Doxycycline 2 (3)
Doxycycline + Quinine 1 (2)
Clindamycin + Quinine 1 (2)
AP + mefloquine 1 (2)
Primaquine 1 (2)
Mefloquine 1 (2)
Supportive care, n (%)  
Erythrocytapheresis 4 (6)
Exchange transfusion 13 (19)
Blood transfusion 9 (13)
Platelets transfusion 1 (2)
Mechanical ventilation 6 (9)
Haemodialysis 5 (7)
  1. AP: atovaquone-proguanil; AL: artemether-lumefantrine; SP: sulphadoxine-pyrimethamine;
  2. Before receiving artesunate, 25 patients (37%) received another anti-malarial drug. The median number of IV dosages of artesunate was 3 (range 1-7) doses. The median cumulative artesunate dose was 600 mg (range 120-1320 mg) or 7.5 mg/kg (range 2.3-18.1) mg/kg. The median time between diagnosis of malaria and first dose of artesunate was 4.0 hours (range 0-47 hours). Treatment was changed to oral anti-malarial drugs after a time of 2 days (range 0-6 days) after first dose of artesunate. The majority received either AP (60%) or AL (29%).